spacer
home > ebr > spring 2002 > has biotechnology forgotten the eye?
PUBLICATIONS
European Biopharmaceutical Review

Has Biotechnology Forgotten the Eye?

For over two decades, the biotechnology industry has been developing therapeutic products based on large molecules. The majority of these products are proteins, from the first trailblazers such as insulin and growth hormone, to the blockbusters like EPO, and subsequently wider classes of molecules such as cytokines, enzymes and antibodies. Yet in all this time, there have been few chronic clinical studies of proteins in eye disease. This is not because the markets are unattractive. Millions of patients suffer from poorly treated diseases in ophthalmology - such as age-related macular degeneration (AMD), or diabetic retinopathy - yet there are still very few medical treatments available. The exception that clearly demonstrates the attractive nature of the ophthalmology market is Visudyne’, developed by QLT Therapeutics Inc. and Novartis. The product transformed QLT from a small Canadian cancer company into a significantly capitalised, internationally known biotech company. This change occurred when the QLT concept of photodynamic therapy, which had previously been applied for several years to cancer with limited success, was applied to AMD. So given this success, why is biotech activity so limited in the eye?


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Tom S Shepherd, President and Chief Executive Officer of Neurotech S.A.

Dr Tom Shepherd is President and Chief Executive Officer of Neurotech S.A., a French-based biotechnology company based in the Genopole science park in Evry near Paris, with a US R&D subsidiary based in Lincoln, Rhode Island. Prior to joining the company in 1998, he was Vice President of Business Development at Intrabiotics Inc, a Californian biotech company now quoted on Nasdaq.
Tom gained his PhD in Biochemistry from the University of Strathclyde in Glasgow, UK, and has 20 years of international management experience in pharmaceuticals and biotechnology, having worked in the UK, the US, Australia, South Korea and France, with a range of companies including Sandoz (now Novartis), Cortecs plc, and ICN Pharmaceuticals.

spacer
Dr Tom S Shepherd
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPhI China opens with analysis pointing to a surge in growth in 2019

Shanghai, 23rd May 2019: New analysis released ahead of CPhI & P-MEC China (#CPhIChina and #PMECChina) co-organized by Informa Markets, CCCMHPIE, and Shanghai Sinoexpo Informa Markets forecasts that China will continue to grow strongly through 2019/20, thanks in part to a marked improvement in its global reputation.
More info >>

White Papers

Running Smarter Trials With Data-Driven Monitoring

PAREXEL

Clinical monitoring remains one of the most important and most costly activities in the clinical research paradigm.  Monitoring provides the operational transparency required by investigators, sponsors, and regulators to make informed decisions about site performance, patient safety, and overall study progress. Yet unlike many clinical trial activities, which have been steadily transformed by technology, the monitoring function itself has changed little.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement